2 Alternative performance measures

In presenting and discussing DSM's financial position, operating results and net results, management uses certain Alternative performance measures not defined by IFRS. These Alternative performance measures (APMs) should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.

To provide clear reporting on the developments of the business, APM adjustments are made that impact the EBIT(DA), net profit, ROCE and the EPS. A reconciliation of these Alternative performance measures to the most directly comparable IFRS measures can be found in the table Alternative performance measures.

The APM adjustments to net profit, as included in the APMs, can be specified as follows:

 

2019

2018

APM adjustments:

 
 
  • Acquisitions/divestments

13

-

  • Other consolidation changes

-

(11)

  • Restructuring

68

68

  • Other

17

11

  • Impairments of PPE and intangible assets

23

32

  • Income tax related to adjustments

(27)

(23)

  • Adjustments to result in associates and joint ventures

(28)

(122)

 
 
 

Total APM adjustments (income)/expense

66

(45)

2019

The APM adjustments in 2019 are listed below:

  • Acquisition and divestment costs of €13 million relate mainly to the acquisition of Yimante, Andre Pectin and Royal CSK

  • Restructuring costs of €68 million relate to project costs of the restructuring projects together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts

  • The other APM adjustment of €17 million relates to the provision for soil cleaning within Corporate Activities

  • Impairments of property, plant and equipment (PPE) and intangible assets of €23 million relate mainly to a development project of DSM Nutritional Products and the impairment of an investment project within DSM Food Specialties

  • APM adjustments to the result from associates and joint ventures of €28 million mainly relate to the step-up to the fair value of the associate Andre Pectin prior to the acquisition

2018

The APM adjustments in 2018 are listed below:

  • Restructuring costs of €68 million relate to project costs of the restructuring projects together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts

  • The other consolidation change relates to the deconsolidation of Yantai Andre Pectin, which led to an accounting profit of €11 million

  • The other APM adjustments of €11 million relate to a changed and remeasured earn-out arrangement with Amyris Brasil

  • Impairments of property, plant and equipment (PPE) and intangible assets of €32 million relate mainly to an R&D building of DSM Nutritional Products in Switzerland and the impairment of a development project within DSM Food Specialties

  • APM adjustments to the result from associates and joint ventures mainly relate to the gain on the sale of the 50% share in DSM Sinochem Pharmaceuticals (DSP) of €109 million and the gain on the sale of the shares in Essential Medical of €13 million

Alternative performance measures

 

2019

2018

 
 
 

Operating profit

954

1,245

Depreciation, amortization and impairments

632

509

EBITDA

1,586

1,754

 
 
 

APM adjustments to EBITDA:

 
 
  • Acquisitions/divestments

13

-

  • Other consolidation changes

-

(11)

  • Restructuring

68

68

  • Other

17

11

Total APM adjustments

98

68

 
 
 

Adjusted EBITDA

1,684

1,822

 
 
 

Operating profit

954

1,245

 
 
 

APM adjustments to Operating profit:

 
 
  • APM adjustments to EBITDA

98

68

  • Impairments of PPE and intangible assets

23

32

Total APM adjustments

121

100

 
 
 

Adjusted operating profit

1,075

1,345

 
 
 

Profit for the year

764

1,079

 
 
 

APM adjustments to:

 
 
  • Operating profit

121

100

  • Result relating to associates/joint ventures

(28)

(122)

Income tax related to APM adjustments

(27)

(23)

Total APM adjustments

66

(45)

 
 
 

Adjusted net profit

830

1,034

Profit attributable to non-controlling interests

(7)

(2)

Dividend on cumulative preference shares

(8)

(8)

 
 
 

Adjusted net profit available to holders of ordinary shares

815

1,024

 
 
 

Earnings per share

 
 
 
 
 

Average number of ordinary shares outstanding (x 1,000)

175,731

175,323

Effect of dilution due to share options (x 1,000)

1,088

1,000

Adjusted average number of ordinary shares outstanding (x 1,000)

176,819

176,323

 
 
 

Earnings per share (EPS) (in €):

 
 
  • Net basic EPS

4.27

6.10

  • Net diluted EPS

4.24

6.06

  • Adjusted net basic EPS

4.64

5.84

  • Adjusted net diluted EPS

4.61

5.81

Alternative performance measures

 

2019

 

2018

 
 
 
 

Capital employed

 
 
 

Intangible assets

3,515

 

3,090

Property, plant and equipment

4,040

 

3,511

Investment grants / drawing rights

(96)

 

(94)

Inventories

2,019

 

1,993

Current receivables

1,698

 

1,738

Current liabilities

(1,865)

 

(2,057)

 
 
 
 

Capital employed at 31 December

9,311

 

8,181

 
 
 
 

Average capital employed

 
 
 

Capital employed at 1 January

8,3961

 

7,766

Capital employed at 31 March

8,907

 

7,740

Capital employed at 30 June

8,735

 

8,115

Capital employed at 30 September

9,330

 

8,220

Capital employed at 31 December

9,311

 

8,181

 
 
 
 

Average capital employed

8,936

 

8,004

 
 
 
 

Adjusted operating profit

1,075

 

1,345

 
 
 
 

ROCE in %

12.0

 

16.8

 
 
 
 

Cash provided by operating activities

1,385

 

1,391

 
 
 
 

Cash impact APM adjustments

57

 

94

Capital expenditure

(627)

 

(673)

Payments regarding drawing rights

(14)

 

(20)

Financial lease IAS 17 (2018)

-

 

18

 
 
 
 

Adjusted net operating free cash flow

801

 

810

  1. Increased by €215 million compared to 31 December 2018 due to the adoption of IFRS 16.